Volume 136, Issue 11 pp. 2659-2667
Epidemiology

Inherited variation at MC1R and ASIP and association with melanoma-specific survival

Nicholas J. Taylor

Nicholas J. Taylor

Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Search for more papers by this author
Anne S. Reiner

Anne S. Reiner

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY

Search for more papers by this author
Colin B. Begg

Colin B. Begg

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY

Search for more papers by this author
Anne E. Cust

Anne E. Cust

Cancer Epidemiology and Services Research, Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia

Search for more papers by this author
Klaus J. Busam

Klaus J. Busam

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY

Search for more papers by this author
Hoda Anton-Culver

Hoda Anton-Culver

Department of Epidemiology, University of California, Irvine, CA

Search for more papers by this author
Terence Dwyer

Terence Dwyer

International Agency for Cancer Research, Lyon, France

Search for more papers by this author
Lynn From

Lynn From

Women's College Hospital, Toronto, ON, Canada

Search for more papers by this author
Richard P. Gallagher

Richard P. Gallagher

British Columbia Cancer Agency, Vancouver, BC, Canada

Search for more papers by this author
Stephen B. Gruber

Stephen B. Gruber

Keck School of Medicine, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA

Search for more papers by this author
Stefano Rosso

Stefano Rosso

Piedmont Tumor Registry, Turin, Italy

Search for more papers by this author
Kirsten A. White

Kirsten A. White

Departments of Internal Medicine, Division of Epidemiology, Biostatistics and Preventive Medicine, University of New Mexico, Albuquerque, NM

Search for more papers by this author
Roberto Zanetti

Roberto Zanetti

Piedmont Tumor Registry, Turin, Italy

Search for more papers by this author
Irene Orlow

Irene Orlow

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY

Search for more papers by this author
Nancy E. Thomas

Nancy E. Thomas

Department of Dermatology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

Search for more papers by this author
Timothy R. Rebbeck

Timothy R. Rebbeck

Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Search for more papers by this author
Marianne Berwick

Marianne Berwick

Departments of Internal Medicine, Division of Epidemiology, Biostatistics and Preventive Medicine, University of New Mexico, Albuquerque, NM

Search for more papers by this author
Peter A. Kanetsky

Corresponding Author

Peter A. Kanetsky

Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Correspondence to: Peter A. Kanetsky, Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL 33612, USA, E-mail: [email protected]Search for more papers by this author
on behalf of the GEM Study Group

on behalf of the GEM Study Group

Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Search for more papers by this author
First published: 10 November 2014
Citations: 25

Author Contributions: N.J.T. and P.A.K. designed the analytic question, interpreted the analysis of data, and prepared the manuscript; A.R., N.J.T., and P.A.K. performed the analysis of data; P.A.K. and T.R. performed all MC1R genotyping; I.O. performed all ASIP genotyping; K.A.W. performed Illumina genotyping; M.B. and C.B. conceived and designed the GEM Study and also contributed to data collection and critical review of the manuscript; All other authors (K.J.B., L.F., P.A.G., H.A.C., A.E.C., T.D., R.P.G., S.G., I.O., S.R., N.E.T., R.Z., and T.R.R.) contributed to data collection and critical review of the manuscript.

Abstract

Melanocortin-1 receptor (MC1R) is a marker of melanoma risk in populations of European ancestry. However, MC1R effects on survival are much less studied. We investigated associations between variation at MC1R and survival in an international, population-based series of single primary melanoma patients enrolled into the Genes, Environment, and Melanoma study. MC1R genotype data was available for 2,200 participants with a first incident primary melanoma diagnosis. We estimated the association of MC1R genotypes with melanoma-specific survival (i.e., death caused by melanoma) and overall survival using COX proportional hazards modeling, adjusting for established prognostic factors for melanoma. We also conducted stratified analyses by Breslow thickness, tumor site, phenotypic index, and age. In addition, we evaluated haplotypes involving polymorphisms near the Agouti signaling protein gene (ASIP) locus for their impacts on survival. Melanoma-specific survival was inversely associated with carriage of MC1R variants in the absence of consensus alleles compared to carriage of at least one consensus allele (hazard ratio (HR) = 0.60; 95% confidence interval (CI): 0.40, 0.90). MC1R results for overall survival were consistent with no association. We did not observe any statistical evidence of heterogeneity of effect estimates in stratified analyses. We observed increased hazard of melanoma-specific death among carriers of the risk haplotype TG near the ASIP locus (HR = 1.37; 95% CI: 0.91, 2.04) when compared to carriers of the most common GG haplotype. Similar results were noted for overall survival. Upon examining the ASIP TG/TG diplotype, we observed considerably increased hazard of melanoma-specific death (HR = 5.11; 95% CI: 1.88, 13.88) compared to carriers of the most common GG/GG diplotype. Our data suggest improved melanoma-specific survival among carriers of two inherited MC1R variants.

Abstract

What's new?

MC1R has important pigmentary biological functions, and inherited variations in the gene are well-known markers of melanoma risk. But whether those variants are also associated with disease survival is unknown. Here, germline variation at MC1R was associated with improved melanoma-specific survival in carriers who lacked a consensus MC1R allele. By contrast, the ASIP TG/TG diplotype, which also is known to be associated with melanoma risk, was linked to a 5-fold increase in hazard of death from melanoma. The findings indicate a complex but influential role for pigmentary genetic loci in melanoma outcomes.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.